PUBLISHER: Grand View Research | PRODUCT CODE: 1587816
PUBLISHER: Grand View Research | PRODUCT CODE: 1587816
The global organ-on-a-chip market size is anticipated to reach USD 952.4 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to register a CAGR of 35.11% from 2025 to 2030. Factors such as the increasing prevalence of chronic disease, the rising need for drug discovery, and growing investment and funding from private and public players are expected to drive the market growth. In addition, increasing competition in the market owing to rising demand from pharmaceutical & biotechnology companies and academic & research institutions is also anticipated to propel the industry growth over the forecast period.
Moreover, the increasing demand for efficient drug discovery techniques, particularly in the context of the rising prevalence of chronic diseases is driving the market growth. For instance, in July 2023, NETRI, in partnership with Axion BioSystems, announced the launch of the NeuroFluidics MEA line. This product line, compatible with Axion's Maestro MultiElectrode Array (MEA) systems, introduces a unique range of compartmentalized microfluidic instruments with an MEA layer. These ready-to-use platforms offer high-throughput solutions for organs-on-chip applications, facilitating advanced research in neurology, dermatology, and other fields crucial for disease study and drug discovery.
Moreover, the liver-on-a-chip segment is a significant driver of the organ-on-a-chip industry, driven by its key role in advancing biomedical research and drug development. For instance, in September 2023, CN Bio, a key player in the organ-on-a-chip industry, collaborated with LifeNet Health LifeSciences, a nonprofit organization recognized globally for its expertise in all-human research solutions. The collaboration aims to supply CN Bio's PhysioMimix OOC range with validated primary human cells from LifeNet Health. In this agreement, LifeNet Health provided supreme-quality, MPS-validated hepatic cells that can be accessed through CN Bio's 'in-a-box' kit for Non-Alcoholic Steatohepatitis (NASH), or directly from LifeNet Health.
Furthermore, North America dominated the organ-on-a-chip industry in 2023 and is projected to grow at the fastest CAGR over the forecast period. The growth is attributed to the presence of key market players in the region and government initiatives. For instance, in March 2023, Bayer AG collaborated with esqLABS and Dynamic42. They introduced a one-year organ-on-a-chip pilot program to reduce testing on animals for drug development in the healthcare industry. Such business initiatives are anticipated to contribute to the growth of the market of the North America region.